Codexis, Inc. CDXS
1.07 USD +0.01 (+0.94%)
Regular-session close
1.07 0.00 +0.13%
After hours · Nov 17, 5:39 PM ET
1.04 Day range 1.12
0.90 52-week range 2.98
- YTD
- -34.36%
- 1 year
- -31.85%
News
benzinga.com Stephens & Co. Reiterates Overweight on Codexis, Maintains $5 Price Target Stephens & Co. analyst Steven Etoch reiterates Codexis (NASDAQ:CDXS) with a Overweight and maintains $5 price target.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Cerenome (NASDAQ:CNSY) shares rose 39.5% to $1.07 during Friday's regular session. The market value of their outstanding shares is at $5.8 million. As per the press release, Q3 earnings came…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers SELLAS Life Sciences Gr (NASDAQ:SLS) stock rose 19.6% to $9.6 during Friday's pre-market session. The market value of their outstanding shares is at $1.6 billion. As per the news, the Q3…
seekingalpha.com Codexis, Inc. (CDXS) Q3 2026 Earnings Call Transcript Codexis, Inc. (CDXS) Q3 2026 Earnings Call Transcript
marketbeat.com What Codexis (CDXS) Said on Its Q3 Earnings Call Codexis NASDAQ: CDXS reported higher third-quarter revenue and a narrower loss as its pharmaceutical biocatalysis business grew, while executives outlined progress toward commercial adoption of the…
zacks.com Codexis (CDXS) Reports Q3 Loss, Beats Revenue Estimates Codexis (CDXS) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.22 per share a year ago.benzinga.com Codexis Q3 EPS $(0.08) Beats $(0.10) Estimate, Sales $19.262M Beat $18.720M Estimate Codexis (NASDAQ:CDXS) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.10) by 20 percent. This is a 63.64 percent increase over losses of $(0.22) per…
benzinga.com Codexis Affirms FY2026 Sales Guidance of $72.000M-$76.000M vs $73.882M Est Codexis (NASDAQ:CDXS) affirms FY2026 sales outlook from $72.000 million-$76.000 million to $72.000 million-$76.000 million vs $73.882 million estimate.
globenewswire.com Codexis Reports Third Quarter 2026 Financial Results and Provides Business Update Reports revenue of $19.3 million for the third quarter of 2026, company reiterates full-year revenue guidance Shared new advances in RNA therapeutic manufacturing at TIDES Europe Entered into a $60…
defenseworld.net Comparing Codexis (NASDAQ:CDXS) and Bionano Genomics (NASDAQ:BNGO) Bionano Genomics (NASDAQ: BNGO - Get Free Report) and Codexis (NASDAQ: CDXS - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two…
globenewswire.com Codexis Enters into $60 Million Term Loan Facility with Trinity Capital REDWOOD CITY, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced…
